2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
January 22nd, 2025
Version: 1
University of Iowa
cancer biology
biorxiv

PI3K regulates TAZ/YAP and mTORC1 axes that can be synergistically targeted

Garcia, K. C.Open in Google Scholar•Khan, A. A.Open in Google Scholar•Ghosh, K.Open in Google Scholar•Sinha, S.Open in Google Scholar•Scalora, N.Open in Google Scholar•DeWane, G.Open in Google Scholar•Fullenkamp, C.Open in Google Scholar•Merritt, N.Open in Google Scholar•Drebot, Y.Open in Google Scholar•Yu, S.Open in Google Scholaret al.

Purpose: Sarcomas are a heterogeneous group of cancers with few shared therapeutic targets. PI3K signaling is activated in various subsets of sarcomas, representing a shared oncogenic signaling pathway. Oncogenic PI3K signaling has been challenging to target therapeutically. An integrated view of PI3K and Hippo pathway signaling is examined to determine if this could be leveraged therapeutically. Experimental design: A tissue microarray containing sarcomas of various histological types was evaluated for PTEN loss and correlated with levels of activated TAZ and YAP. PI3K and Hippo pathways were dissected in sarcoma cell lines. The role of TAZ and YAP were evaluated in a PI3K-driven mouse model. The efficacy of mTORC1 inhibition and TEAD inhibition were evaluated in sarcoma cell lines and in vivo. Results: PI3K signaling is frequently activated in sarcomas due to PTEN loss (in 30-60%), representing a common therapeutic target. TAZ and YAP are transcriptional co-activators regulated by PI3K and drive a transcriptome necessary for tumor growth in a PI3K-driven sarcoma mouse model. Combination therapy using IK-930 (TEAD inhibitor) and everolimus (mTORC1 inhibitor) synergistically diminished proliferation and anchorage independent growth of PI3K-activated sarcoma cell lines at low, physiologically achievable doses. Furthermore, this combination therapy showed a synergistic effect in vivo, reducing tumor proliferation and size. Conclusions: TAZ and YAP are transcriptional co-activators downstream of PI3K signaling, a pathway that has lacked a well-defined oncogenic transcription factor. This PI3K-TAZ/YAP axis exists in parallel to the known PI3K-Akt-mTORC1 axis allowing for synergistic combination therapy targeting the TAZ/YAP-TEAD interaction and mTORC1 in sarcomas.

Similar Papers

biorxiv
Sat Jul 05 2025
Cell Settling, Migration, and Stochastic Cancer Expression Suggest Potassium Flux Per H+- Sensitive KCN Members Associated with Oncogenes and Histone/DNA Modulators Potentially Initiates pH-Reversal
Attraction of glioblastoma cells to potassium was suspected when cells clustered around dying cells and they migrated towards serum (high [K+]) and a positive potassium gradient. Potassium channel proteins (KCN family, 90 members) mediating altered transmembrane flux may provide K+ that releases H+ bound to inner membranes in cancer cells for cytosolic proton transfer (possibly Grotthuss) to extru...
Beckner, M.
biorxiv
Fri Jul 04 2025
Spatial Proteomics of the Normal Breast Collagen Stroma: Links to BI-RADS Categories and Body Mass Index
Collagen breast stroma is the basis of increased breast density and a well-established breast cancer risk factor, yet proteomic regulation of normal breast stroma remains poorly defined. This study reports spatial regulation of the collagen proteome in normal breast tissue sections annotated by clinical characteristics. Normal breast samples from the Susan G. Komen tissue bank included data on gen...
Dunne, J. B.
•
Rujchanarong, D.
•
Park, Y.
•
Macdonald, J. K.
...•
Angel, P. M.
biorxiv
Fri Jul 04 2025
Multi-omic analysis of colorectal adenocarcinoma identifies a new subtype of myofibroblastic cancer-associated fibroblast expressing high level of B7-H3 and with poor prognosis value.
The high mortality rate of colorectal cancer (CRC) combined with the lack of non-toxic and efficient personalized treatments makes it urgent to develop new targeted therapies for this disease. B7-H3 appears to be a good target as it is overexpressed in tumor tissue compared to normal tissue. However, B7-H3 is a molecule with ambivalent functions and is expressed by different cell types. This compl...
Picard, M.
•
Guille, A.
•
Finetti, P.
•
De Rauglaudre, B.
...•
Mamessier, E.
biorxiv
Fri Jul 04 2025
An organotypic in vitro model of human papillomavirus-associated precancerous lesions allowing automated cell quantification for preclinical drug testing
Oncogenic human papillomaviruses (HPV) are causally responsible for invasive cancers and precancerous lesions. These lesions represent a considerable disease burden worldwide, yet no causally effective treatments are available. The development of HPV tumor models realistically reflecting the in vivo treatment situation is necessary for finding new effective and tissue-sparing treatments. This stud...
Köhler, R. M.
•
Stark, H.-J.
•
Martin, I.
•
Altmann, J.
...•
Prigge, E.-S.
biorxiv
Fri Jul 04 2025
The IFN I response in tumor cells is shaped by PARP7-p300/CBP interactions through distinct loss- and gain-of-function mechanisms
PARP7, a mono-ADP-ribosyl (MAR) transferase, is a key suppressor of the type I interferon (IFN-I) IFNb in various tumor cells and a validated drug target. This negative regulation is reversed by small-molecule inhibitors of PARP7 catalytic activity, resulting in increased IFNb expression. Yet, the mechanism of action of PARP7 inhibitors remains unclear because the relevant substrates of PARP7-medi...
Siordia, I. R.
•
Rieth, S.
•
Jeltema, D.
•
Morgan, R.
...•
Cohen, M. S.
biorxiv
Fri Jul 04 2025
Punctuated mutagenesis promotes multi-stepevolutionary adaptation in human cancers
The rate of acquisition of genomic changes in cancer has been the topic of much discussion, with several recent investigations finding evidence of punctuated evolution instead of gradual accumulation of such changes. Despite forays into the description and quantification of these punctuated events, the effects of such events on subsequent cancer evolution remain incompletely understood. Here we in...
Michor, F.
•
Graser, C. J.
•
Wu, W.
•
Christini, C.
•
Peljak, M.
biorxiv
Fri Jul 04 2025
Bioelectric and Epigenetic Landscapes in Lateralized Breast Tumors Reveal Distinct Tumor Microenvironment Signatures.
Cell communication within the tumor microenvironment (TME) plays a pivotal role in cancer progression, yet little is known about whether this communication differs between anatomically paired organs. Here, we report that breast tumors arising in the left (L) versus right (R) mammary glands exhibit significant asymmetry in composition, bioelectric state, and epigenetic regulation suggesting the exi...
Real, S.
•
Laurito, S.
•
Gonzalez, P.
•
Bello, O.
...•
Moreno, M. R.
biorxiv
Fri Jul 04 2025
DIFFERENTIAL ROLES OF RAD18 IN REPRESSING CARCINOGEN- AND ONCOGENE-DRIVEN MUTAGENESIS IN VIVO
The DNA repair protein RAD18 activates Y-family Trans-Lesion Synthesis (TLS) DNA polymerases that are DNA damage-tolerant and potentially error-prone. RAD18 is also frequently overexpressed and pathologically activated in cancer cells. However, the extent to which RAD18 shapes cancer genomes and impacts tumorigenesis is unclear. Therefore, we tested the effect of Rad18 status on chemically-induced...
Anand, J.
•
Brown, B. W.
•
Lou, J.
•
Gu, Q.
...•
Vaziri, C.
biorxiv
Thu Jul 03 2025
Interplay of YEATS2 and GCDH regulates histone crotonylation and drives EMT in head and neck cancer
The regulation of gene expression is an integral cellular process orchestrated by epigenetic marks like histone modifications. Perturbations in the activity or abundance of epigenetic factors can lead to tumorigenesis. Remarkably, several metabolites influence the epigenetic landscape in cells. Here, we investigated the interplay between a highly expressed epigenetic factor, YEATS2, and a metaboli...
Pant, D.
•
KAKANI, P.
•
Joshi, R.
•
Sabu, A.
...•
Shukla, S.
biorxiv
Thu Jul 03 2025
Multi-gradient Permutation Survival Analysis Identifies Mitosis and Immune Signatures Steadily Associated with Cancer Patient Prognosis
The inconsistency of the association between genes and cancer prognosis is often attributed to many variables that contribute to patient survival. Whether there exist the Genes Steadily Associated with Prognosis (GEARs) and what their functions are remain largely elusive. Here we developed a novel method named "Multi-gradient Permutation Survival Analysis " (MEMORY) to screen the GEARs by using RN...
Cai, X.
•
Ye, Y.
•
Liu, X.
•
Fang, Z.
...•
Ji, H.